[1] |
LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke.
A bioequivalence study of generic and brand clozapine in schizophrenic patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
|
[2] |
YAN Pan, SHI Jianfei, LI Jing, WANG Shengdong, WANG Shuqi, WANG Chengpeng, SONG Mingfen.
Effects of DRD2 and 5-HTR2A gene polymorphisms and their interaction on olanzapine in the treatment of schizophrenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1131-1138.
|
[3] |
WAN Ping, LIU Liang, ZHANG Ping, ZHANG Zhongdong.
Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1024-1029.
|
[4] |
FAN Yao, XUE Yong, WANG Xin, CHEN Xuefei, ZHANG Xu, YAO Yingshui, SHEN Chong.
Association analysis of apolipoprotein E polymorphisms and weight loss among schizophrenia patients with risperidone treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 288-295.
|
[5] |
CAO Ting, LI Nana, CAI Hualin.
Progress in neurosteroids related to the pathogenesis and treatment of schizophrenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 709-714.
|
[6] |
QIAN Wei, ZHENG Linhai, YANG Di, YE Fangqin, YANG Jin.
A preliminary study on the ethical risk assessment of human bioequivalence trial
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1077-1080.
|
[7] |
LILi, YANG Jinbo.
Application and progress of physiologically-based oral absorption model in clinical development of generic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 961-965.
|
[8] |
CUI Lijun, PAN Xin, ZHU Jielin, LI Jianhua.
Effect of paliperidone and olanzapine on patients with first-episode schizophrenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 466-470.
|
[9] |
ZHOU Yong, Chen Xuefang, HUANG Hanjin.
Efficacy and safety of amisulpride for schizophrenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1152-1157.
|
[10] |
YU Shan-shan, ZHANG Zheng-fu, LI Zheng-qi.
Investigation and countermeasures to the current status of the generics quality consistency evaluation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 118-120.
|
[11] |
HANG Rong-hua, LI Ye-ping, WU Ming-fei, LI Rui.
Relationship on medication compliance, antipsychotic side-effects and social support in schizophrenia outpatients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 912-915.
|
[12] |
NI Ping, LV Hai-long, GUO Xiao-feng, ZHANG Li-li, XU Lin-yong.
Comparison of curative effect and clinical influence factors of risperidone and olanzapine in the treatment of acute phrase of schizophrenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 182-185.
|
[13] |
TANG Ya-mei, ZHANG Xiang-hui, LIU Yong.
Concentration change of NE, 5-HT and their metabolites in brain tissue in schizophrenia developmental models rat repeatedly treated with MK-801
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 721-726.
|
[14] |
HANG Rong-hua, CHENG Wan-liang, WANG Rui-quan, WU Ming-fei.
Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 812-815.
|
[15] |
LIU Lin-jing, XIU Mei-hong, ZHANG Xiang-yang, CHEN Da-chun.
Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 313-317.
|